Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the field of medication safety in the United States.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Tabula Rasa HealthCare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 43T's share price has been volatile over the past 3 months.
7 Day Return
DE Healthcare Services
1 Year Return
DE Healthcare Services
Return vs Industry: 43T underperformed the German Healthcare Services industry which returned 12% over the past year.
Return vs Market: 43T exceeded the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Tabula Rasa HealthCare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Tabula Rasa HealthCare undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 43T (€45) is trading below our estimate of fair value (€88.36)
Significantly Below Fair Value: 43T is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 43T is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: 43T is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 43T's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 43T is overvalued based on its PB Ratio (5.9x) compared to the DE Healthcare Services industry average (2.8x).
How is Tabula Rasa HealthCare forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 43T is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 43T is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 43T is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 43T's revenue (15% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: 43T's revenue (15% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 43T's Return on Equity is forecast to be high in 3 years time
How has Tabula Rasa HealthCare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 43T is currently unprofitable.
Growing Profit Margin: 43T is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 43T is unprofitable, and losses have increased over the past 5 years at a rate of -35.6% per year.
Accelerating Growth: Unable to compare 43T's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 43T is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (5.9%).
Return on Equity
High ROE: 43T has a negative Return on Equity (-17.48%), as it is currently unprofitable.
How is Tabula Rasa HealthCare's financial position?
Financial Position Analysis
Short Term Liabilities: 43T's short term assets ($94.5M) exceed its short term liabilities ($40.0M).
Long Term Liabilities: 43T's short term assets ($94.5M) do not cover its long term liabilities ($266.8M).
Debt to Equity History and Analysis
Debt Level: 43T's debt to equity ratio (122%) is considered high.
Reducing Debt: 43T's debt to equity ratio has reduced from 2088% to 122% over the past 5 years.
Inventory Level: 43T has a low level of unsold assets or inventory.
Debt Coverage by Assets: 43T's debt is not covered by short term assets (assets are 0.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 43T has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 43T has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Tabula Rasa HealthCare's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 43T's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 43T's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 43T's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 43T's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 43T's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Calvin Knowlton (69yo)
Dr. Calvin H. Knowlton, BSc Pharm, MDiv, Ph.D., is a Co-Founder of Tabula Rasa Healthcare, Inc. and has been its Chairman and Chief Executive Officer since June 2014. Dr. Knowlton founded CareKinesis, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Calvin's total compensation ($USD3.54M) is above average for companies of similar size in the German market ($USD1.36M).
Compensation vs Earnings: Calvin's compensation has increased whilst the company is unprofitable.
|CFO & Secretary||5.83yrs||US$1.66m||1.03% $10.5m|
|Chief Operating Officer||5.83yrs||no data||1.06% $10.8m|
|Corporate Controller & Chief Accounting Officer||2.17yrs||no data||0.23% $2.3m|
|Chief Technology Innovation Officer & EVP of eHealth Services||1.25yrs||no data||no data|
|Chief Information Officer||5.83yrs||no data||no data|
|Chief Scientific Officer||4.58yrs||no data||no data|
|Chief Administrative Officer||5.17yrs||no data||no data|
|Senior Vice President of Investor Relations & Corporate Development||0.083yr||no data||no data|
Experienced Management: 43T's management team is seasoned and experienced (5.5 years average tenure).
|Lead Independent Director||no data||US$164.50k||0.057% $577.5k|
|Independent Director||1.75yrs||US$523.86k||0.051% $519.5k|
|Independent Director||3.08yrs||US$146.00k||0.061% $618.8k|
|Independent Director||1.75yrs||US$506.36k||0.051% $519.5k|
|Independent Director||2.67yrs||US$141.25k||0.038% $387.8k|
|Independent Director||1.42yrs||US$570.59k||0.050% $509.0k|
|Independent Director||1.08yrs||no data||0.045% $461.3k|
Experienced Board: 43T's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 43T insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.
Tabula Rasa HealthCare, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Tabula Rasa HealthCare, Inc.
- Ticker: 43T
- Exchange: DB
- Founded: 2009
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$1.103b
- Listing Market Cap: US$1.020b
- Shares outstanding: 21.17m
- Website: https://www.tabularasahealthcare.com
Number of Employees
- Tabula Rasa HealthCare, Inc.
- 228 Strawbridge Drive
- Suite 100
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TRHC||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Sep 2016|
|43T||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2016|
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the field of medication safety in the United States. The company’s proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems. The company’s cloud-based software applications also comprise RxCompanion, a medication therapy management software platform for the identification and resolution of medication and other health related problems; TruChart, an electronic health record (EHR) system for Programs of All-Inclusive Care for the Elderly (PACE) programs; and PACElogic, which deliver real-time sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination, planning, integration with community-based providers, and various Federal and State required reporting for PACE organizations and small health plans. Tabula Rasa HealthCare, Inc. also offers clinical pharmacist collaboration, prescription fulfillment and reminder packaging, and pharmacy cost management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2018, it served 224 healthcare organizations. The company offers its cloud-based software solutions to prescribers, pharmacists, and healthcare organizations for managing the medication-related needs of their patients. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 00:25|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.